Axcella Health Inc (AXLA)

Etorro trading 970x250
Axcella Health Inc (AXLA) Logo

About Axcella Health Inc

Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. It treats complex diseases and enhances health using endogenous metabolic modulator compositions. The company’s lead product candidates include AXA1665 for the treatment of overt hepatic encephalopathy; and AXA1125 for treating non-alcoholic steatohepatitis. It also develops AXA4010, a hematology product candidate; and AXA2678, a muscle product candidate. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts. Address: 840 Memorial Drive, Cambridge, MA, United States, 02139

Axcella Health Inc News and around…

Latest news about Axcella Health Inc (AXLA) common stock and company :

Axcella, Now Axcella Therapeutics, to Host Virtual R&D Day on October 26, 2021
19 Oct, 2021 FinancialContent

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using endogenous metabolic modulator (EMM) compositions, today announced that it will host a virtual R&D Day on Tuesday, October 26, 2021, at 10:00 a.m. ET. The event will feature presentations from multiple key opinion leaders (KOLs) as well as Axcella’s management team. Topics will include the company’s next clinical program (to be announced the day of the event), its ongoing programs in overt hepatic encephalopathy (OHE) and non-alcoholic steatohepatitis (NASH), and its platform.

Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize Agricultural Solutions to Address Climate Change
13 Oct, 2021 Yahoo! Finance

Invaio Sciences, Inc., a Flagship Pioneering company unlocking the potential of natural systems to accelerate the transition to sustainable agriculture to urgently address climate change, has entered into a $50 million loan and security agreement with K2 HealthVentures (K2HV), a healthcare and life sciences-focused investment firm.

The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
12 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
06 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Axcella Announces Upcoming Investor Conference Presentation
05 Oct, 2021 FinancialContent

Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that management will be presenting at the H.C. Wainwright 5th Annual NASH Investor Conference.

The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
30 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Axcella's Leading Drug Candidate for Overt Hepatic Encephalopathy Offers Hope in a Market Requiring Innovation
28 Sep, 2021 FinancialContent

Image by Ousa Chea on Unsplash The clinical-stage biotech company Axcella (NASDAQ: AXLA) uses endogenous metabolic modulators (EMMs) ...

Axcella Health Inc. (NASDAQ: AXLA) Featured in Coverage of Benzinga’s Healthcare Small Cap Conference
24 Sep, 2021 FinancialContent
Benzinga's Top Ratings Upgrades, Downgrades For September 22, 2021
22 Sep, 2021 FinancialContent

Upgrades Argus Research upgraded the previous rating for Simon Property Group Inc (NYSE:SPG) from Hold to Buy. In the ...

10 Biggest Price Target Changes For Wednesday
22 Sep, 2021 FinancialContent

Piper Sandler boosted the price target for Adobe Inc. (NASDAQ: ADBE) from $600 to $670. Adobe shares fell 3.5% to $623.50 in ...

Analysts Forecast 42% Upside For The Holdings of IWC
21 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Micro-Cap ETF (IWC), we found that the implied analyst target price for the ETF based upon its underlying holdings is $201.09 per unit.

Axcella's First-of-Its-Kind NASH Treatment Shows Promising Early Results in Human Trials
09 Sep, 2021 FinancialContent

Image Provided By Pixabay The American Journal of Gastroenterology recently published findings from a clinical study of AXA1125, a ...

Axcella Announces Upcoming Investor Conference Presentation
07 Sep, 2021 FinancialContent

Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that management will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference.

What Is The Ownership Structure Like For Axcella Health Inc. (NASDAQ:AXLA)?
02 Sep, 2021 Yahoo! Finance

The big shareholder groups in Axcella Health Inc. ( NASDAQ:AXLA ) have power over the company. Generally speaking, as a...

12 Health Care Stocks Moving In Wednesday's After-Market Session
01 Sep, 2021 FinancialContent

Gainers INmune Bio (NASDAQ:INMB) shares moved upwards by 18.76% to $28.35 during Wednesday's after-market session. Trading volume ...

Breakthrough Multi-Targeted Drug Candidates Puts Axcella at Forefront of Liver Disease Treatment Market
30 Aug, 2021 FinancialContent

Image Provided By Unsplash Liver diseases like cirrhosis and nonalcoholic steatohepatitis (NASH) are deadly and afflict millions of ...

We Did The Math FDM Can Go To $76
16 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Dow Jones Select MicroCap Index Fund ETF (FDM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $75.83 per unit.

Axcella Announces Publication in The American Journal of Gastroenterology of Positive Results from AXA1125-003 in Subjects With Presumed NASH
16 Aug, 2021 FinancialContent

Axcella (Nasdaq:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced the publication of results from the company’s AXA1125-003 clinical study in The American Journal of Gastroenterology entitled “Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease.” Based on the positive findings from this study, Axcella recently initiated its EMMPACT℠ Phase 2b clinical trial of AXA1125 in patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH).

Benzinga's Top Ratings Upgrades, Downgrades For July 30, 2021
30 Jul, 2021 FinancialContent

Upgrades According to Craig-Hallum, the prior rating for Gentherm Inc (NASDAQ:THRM) was changed from Hold to Buy. For ...

Axcella Reports Second Quarter Financial Results and Provides Business Update
29 Jul, 2021 FinancialContent

Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced financial results for the second quarter ended June 30, 2021 and provided a business update.

Axcella to Report Second Quarter 2021 Financial Results on July 29, 2021
22 Jul, 2021 FinancialContent

Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that it plans to report its second quarter 2021 financial results and other business updates on July 29, 2021. The company will host a conference call at 8:30 a.m. ET that morning.

Implied FDM Analyst Target Price: $75
12 Jul, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Dow Jones Select MicroCap Index Fund ETF (FDM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $74.56 per unit.

61 Biggest Movers From Yesterday
08 Jul, 2021 FinancialContent

Gainers Newegg Commerce, Inc. (NASDAQ: NEGG) shares surged 148.4% to close at $67.57 on Wednesday after jumping around 42% on ...

42 Stocks Moving In Tuesday's Mid-Day Session
06 Jul, 2021 FinancialContent

Gainers Orbsat Corp. (NASDAQ: OSAT) shares jumped 74% to $9.47. BSQUARE Corporation (NASDAQ: BSQR) shares jumped 48.2% to $5.90 ...

Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2021
06 Jul, 2021 FinancialContent

Upgrades According to Citigroup, the prior rating for ORIC Pharmaceuticals Inc (NASDAQ:ORIC) was changed from Neutral to ...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
06 Jul, 2021 FinancialContent

Gainers Advaxis (NASDAQ:ADXS) stock rose 46.9% to $0.69 during Tuesday's pre-market session. The market value of ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
06 Jul, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're getting right back into the swing of things today after the weekend with a look at the biggest pre-market stock movers for Tuesday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now It doesn’t matter if you have $500 in savings or $5 million. Do this now. Top Stock Picker Reveals His Next Potential 500% Winner

Axcella Announces Initiation of EMMPOWER℠ Phase 2 Clinical Trial of AXA1665
30 Jun, 2021 FinancialContent

Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that it has activated initial clinical sites and patient screening for its global Phase 2 clinical trial of AXA1665, the company’s multi-targeted oral product candidate for the reduction in risk of recurrent overt hepatic encephalopathy (OHE).

Axcella Accumulating Assets; Multiple Therapies in the Pipeline
13 Jun, 2021 Yahoo! Finance

Time in the market beats timing the market, as the old adage goes. This platitude plays particularly well regarding biotechnology stocks, as one will want to be invested in these stocks well before any big news comes out. Axcella Health Inc. (AXLA) is no exception, as the company is making strides on breakthrough therapies. Analysts are bullish on the stock. One such analyst is Keay Nakae of Chardan Capital Markets, who assigned a Buy rating and a price target of $10. While this price target rep

Best Biotech Penny Stocks to Buy? 3 to Watch Before Monday
11 Jun, 2021 FinancialContent

Axcella Health Inc (AXLA) is a NASDAQ Common Stock listed in , ,

970x250